Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. - Wikidata - wikimedia - TriplyDB

Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients.

Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients.

http://www.wikidata.org/entity/Q36851259

about

My approach to the treatment of scleroderma Neurological complications in chronic kidney disease Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients: a nationwide data survey and propensity analysis.Protocol of randomized control trial for effectiveness of angiotensin receptor blockers on blood pressure control among euvolemic hypertensive hemodialysis patients.Comparative Effectiveness of Renin-Angiotensin System Antagonists in Maintenance Dialysis Patients.Beneficial effects on arterial stiffness and pulse-wave reflection of combined enalapril and candesartan in chronic kidney disease--a randomized trial Hyperkalemia of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in hemodialysis: a meta-analysis.Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis.Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study.Add-on Protective Effect of Pentoxifylline in Advanced Chronic Kidney Disease Treated with Renin-Angiotensin-Aldosterone System Blockade - A Nationwide Database Analysis.Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.The (pro)renin receptor. A decade of research: what have we learned?Impact of race on cumulative exposure to antihypertensive medications in dialysis Efficacy of Losartan in the management of Post-Dialysis Euvolemic Hypertension (HELD-Trial): A Single-Blind Randomized Control Trial.Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis.The effectiveness and safety of angiotensin-converting enzyme inhibition or receptor blockade in vascular diseases in patients with hemodialysis.Prevention, detection and management of early chronic kidney disease: a systematic review of clinical practice guidelines.Stem cell therapy for cardiac regeneration: hits and misses.Molecular regulation of the renin-angiotensin system in haemodialysis patients.Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension.Impact of drugs on intradialytic hypotension: Antihypertensives and vasoconstrictors.Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.Impact of use of angiotensin II receptor blocker on all-cause mortality in hemodialysis patients: prospective cohort study using a propensity-score analysis.The crossroad of RAAS modulation, inflammation, and oxidative stress in dialysis patients: light at the end of the tunnel?Safety and Efficacy of Losartan 50 mg in Reducing Blood Pressure among Patients with Post-Dialysis Euvolemic Hypertension: A Randomized Control Trial.The Combination of Beta Blockers and Renin-Angiotensin System Blockers Improves Survival in Incident Hemodialysis Patients: A Propensity-Matched Study.Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.Interactive Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers or Their Combination on Survival of Hemodialysis Patients.Imbalanced plasma ACE and ACE2 level in the uremic patients with cardiovascular diseases and its change during a single hemodialysis session.Renin-angiotensin system blockade in heart failure patients on long-term haemodialysis in Taiwan.Patterns of progression of chronic kidney disease at later stages.

P2860

Q24618843-09F24C33-52CF-427C-B605-D1597A4DF77D Q28072242-F69BE610-72C5-4A4E-966C-2A662F1D9A80 Q30886019-D69F77F3-3C6F-451D-9DD9-7F6D84EA18AB Q33621194-1FDC74D5-D3DF-40B1-AC39-CE9B3D883B55 Q33730477-B8FA9E09-3E60-455E-B3C5-9F07A77C3891 Q34364230-F9265049-A096-487E-BFD2-1D2979E4A28C Q34449065-0F9BD7DD-A7F4-4EF3-8EC6-A9D13DF8DADE Q35715691-95A42748-AE6C-47FC-952D-F2C5B794EF2C Q35818228-E257BEFC-8647-4375-9E19-0B919A038D58 Q36323673-7BC10F2D-0AF8-47F9-94E8-525676B847AA Q36497887-E8FCD2D5-4F9D-4681-9E24-8BCB9E92D2A8 Q36557476-36435D7D-1E46-4E58-91B6-E66B47134E81 Q36764881-2EC501F3-5343-4232-BF9B-2AAC3D9F2273 Q37476022-1C0DB8EB-2DC5-4898-962B-F609D7BA32C3 Q37620992-77167308-3AC5-4F7F-A9E8-38D8A5935D3C Q37737326-55A84823-AF13-49E5-8AFC-D37BCEC6BB67 Q38118372-321DF5B8-FF64-40E7-96FA-E3B5928052AB Q38601272-7A70E185-EC83-4470-A3FA-8325EFA86A46 Q39147047-18DA070E-6F55-4032-935B-CDF0C20CB743 Q39264079-2C3D2612-2972-4D2E-8D25-782BADC88C3E Q39417554-6243F2B8-A33D-44E8-BCE7-4C1B4A6C1556 Q39532143-2D85DD50-4427-46DD-880F-FF08C01430BA Q40394425-1FB1D7D0-752A-4E01-9581-AC42264F6CDC Q43066725-CC0ACB87-6420-41DA-8F56-A146194545FB Q47105380-D6BD2645-271F-4DB8-86B2-E5D11F5DD6FB Q47137687-3BB747FC-3C7E-4B9E-9933-AE53E011F31C Q47257220-EB115633-7100-4A75-BC80-643691C925CF Q47434892-DE32C0E1-EC9C-47C0-A212-94BB3D461A8D Q48269756-0A358C08-7687-4E98-A65B-D2946022E4A3 Q53110490-6132056F-0714-44D3-8EF7-E6437D6426EA Q55000470-D70D6029-3C02-44B1-AB0F-D4DB38F31ACD

P2860

Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients.

http://www.wikidata.org/entity/Q36851259

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Combined angiotensin-convertin ...... eath in hemodialysis patients.

@en

type

label

Combined angiotensin-convertin ...... eath in hemodialysis patients.

@en

prefLabel

Combined angiotensin-convertin ...... eath in hemodialysis patients.

@en

P1433

Q36851259-09893063-A1BB-4337-8A8F-7984943ED8B1

P1476

Q36851259-86083525-6166-40EE-8BAE-5A1E764C0861

P2093

Q36851259-0A0097D7-599B-47DF-83D1-F98C04BCC4E2

Q36851259-26325C77-2353-470F-AE5E-A88C1D0804A1

Q36851259-2FCA722F-4C55-4649-A289-819181DB1A74

Q36851259-57994DE8-DEA9-412F-8A31-BFD0EABE88EB

Q36851259-5FFE99CE-8656-4E12-98DE-040CED1DBD77

Q36851259-F1C15376-728C-48E3-BEA0-3CDD60B1051F

P2860

Q36851259-1110A635-3C5C-4497-8CC9-6569E88466E7

Q36851259-12493EDD-3E59-4F1A-8045-2893C043D43E

Q36851259-18F68047-C957-49BE-B847-B0E724D2672E

Q36851259-1EFE31F2-F08B-422D-B76F-644A500AA99B

Q36851259-2EED641D-5A2C-4443-8784-A699CF19F5FA

Q36851259-33F2A84C-7587-42F1-BF36-78E8F0497994

Q36851259-3BC5BE47-A6C2-459D-8C33-FBD319F12925

Q36851259-408581DD-DDF1-4969-A96A-95BAC8E6D0A7

Q36851259-47F848A8-33EE-40F3-969D-221ADD9DB557

Q36851259-4E793054-E8F5-4A88-8480-993606CDAB24

P2888

Q36851259-CA0E984C-37FF-480C-B151-CE2D7E0A7A08

P304

Q36851259-A2A3D05C-0C5B-42DA-B6C8-BDBF1802FD0A

P31

Q36851259-13984DAB-9A5E-48B0-8538-8B02D8CDAEFF

P356

Q36851259-388F77BD-AB28-4A24-8E7C-785E174D2FDC

P407

Q36851259-62F7655E-6DAC-4E89-85A2-052D91740C77

P433

Q36851259-BED7E970-0044-4F9B-99CB-BB1CB68DAE9C

P478

Q36851259-28A4C17C-5735-4CBA-BC0A-F0FBA75F3790

P577

Q36851259-277BD7E5-D788-48DD-BDAA-05BC962C8AC3

P5875

Q36851259-587F2601-333E-4072-A91B-1FF30A821C08

P698

Q36851259-652AF2F7-EED9-418B-8283-21082456BF3F

P932

Q36851259-281267EB-D547-48ED-BD8C-A98F5A6EFB25

P356

P1433

Kidney International

P1476

Combined angiotensin-convertin ...... eath in hemodialysis patients.

@en

P2093

Chang Yu

http://www.w3.org/2001/XMLSchema#string

Jorge L Gamboa

http://www.w3.org/2001/XMLSchema#string

Kevin E Chan

http://www.w3.org/2001/XMLSchema#string

Nancy J Brown

http://www.w3.org/2001/XMLSchema#string

Raymond M Hakim

http://www.w3.org/2001/XMLSchema#string

T Alp Ikizler

http://www.w3.org/2001/XMLSchema#string

P2860

HIVAN and medication use in chronic dialysis patients in the United States: analysis of the USRDS DMMS Wave 2 study

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease.

Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

P2888

P304

978-985

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/KI.2011.228

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

80

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51508524

http://www.w3.org/2001/XMLSchema#string

P698

21775975

http://www.w3.org/2001/XMLSchema#string

P932

3656595

http://www.w3.org/2001/XMLSchema#string